Dr. Reddy’s Lab Share Price Closes 1.73% Higher on January 08, 2025

On January 08, 2025, Dr. Reddy’s Lab share price ended 1.73% higher at ₹1,374.10, while the BSE benchmark Sensex closed 50.62 points to 78,148.49. Dr Reddy’s Lab share price reached a 52-week high of ₹1,420.20 on August 21, 2024, and a 52-week low of ₹1,104.69 on January 18, 2024. As per BSE, the total traded volume for the stock stood at 0.82 lakh shares with a turnover of ₹11.32 crore.

At the current price, Dr. Reddy’s Lab shares are trading at a price-to-earnings (P/E) ratio of 4.77x, based on its trailing 12-month earnings per share (EPS) of ₹288.19, and a price-to-book (P/B) ratio of 0.86, according to exchange data.

Shareholding Details

As of December 31, 2024, promoters held a 26.64% stake in Dr. Reddy’s Lab shares, while Domestic Institutional Investors (DIIs) owned 21.48%, and Foreign Institutional Investors (FIIs) held 27.53%.

Q2 FY25 Performance 

Healthcare major Dr. Reddy’s Laboratories reported a consolidated net profit of ₹1,255 crore for the second quarter of FY25, a decline from ₹1,480 crore in the same period last year. The company’s revenue from operations for the July-September 2024 quarter stood at ₹8,016 crore. Meanwhile, EBITDA for the period was reported at ₹2,280 crore, reflecting the company’s performance amid evolving market conditions.

About Dr. Reddy’s Lab

Founded in 1984 by Kallam Anji Reddy, Dr. Reddy’s Laboratories has grown into a global pharmaceutical powerhouse headquartered in Hyderabad, India. The company produces a diverse range of pharmaceuticals, including generic drugs, over-the-counter medicines, vaccines, diagnostics, biologics, and dietary supplements.

With a focus on research in critical areas such as diabetes, cardiovascular diseases, anti-infectives, inflammation, and cancer, Dr Reddy has established a significant presence in markets like India, the US, Europe, Russia, China, and Brazil.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.